Spoken approach
say this aloud Free preview- When discussing landmark nephrology trials, I categorize them by subspecialty to structure my thinking.
- First, in transplantation, the ELITE-SYMPHONY trial was pivotal. It established that a regimen of low-dose tacrolimus, mycophenolate mofetil, and steroids, with IL-2 receptor antagonist induction, provides the best balance of efficacy and safety, and it remains our standard of care.
- In glomerular disease, particularly ANCA vasculitis, the RAVE trial demonstrated that rituximab is non-inferior to cyclophosphamide for remission induction. Subsequently, the PEXIVAS trial showed no benefit for routine plasma exchange in most patients and supported using lower-dose steroid regimens, which has de-escalated our treatment protocols significantly.
+ 7 more steps of the spoken answer for subscribers